Sublingual tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a randomized, placebo-controlled crossover study

Key Points

• The aim was to evaluate the effectiveness of sublingual THC/CBD in reducing chronic pain in epidermolysis bullosa.
• Randomized, double-blind, placebo-controlled crossover design
• Involved eight adults with epidermolysis bullosa
• Treatment included sublingual 10% THC and 5% CBD
• 75% of participants reported at least a 30% reduction in global pain
• Analgesic use was halved during active treatment
• Mild adverse events were observed, but no significant pain affect change occurred